Boehringer Ingelheim’s, Lilly's Jardiance gets new indication

SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Boehringer Ingelheim and Eli Lilly and Co.’s Jardiance (empagliflozin) tablets, the companies announced Monday. The drug is now approved to reduce the risk of cardiovascular death in adults with Type 2 diabetes. 

 

“As the only diabetes treatment approved by the FDA to reduce the risk of cardiovascular death, Jardiance represents a tremendous step forward in our efforts to reduce the impact of heart disease among adults with type 2 diabetes and cardiovascular disease,” Boehringer Ingelheim president and CEO Paul Fonteyne said. “This approval is another example of our commitment to the discovery and development of treatment options for adults with Type 2 diabetes. We believe that Jardiance is an important treatment option for this patient population.”